TY - JOUR
T1 - ELMO1 signaling is a promoter of osteoclast function and bone loss
AU - Arandjelovic, Sanja
AU - Perry, Justin S.A.
AU - Zhou, Ming
AU - Ceroi, Adam
AU - Smirnov, Igor
AU - Walk, Scott F.
AU - Shankman, Laura S.
AU - Cambré, Isabelle
AU - Onengut-Gumuscu, Suna
AU - Elewaut, Dirk
AU - Conrads, Thomas P.
AU - Ravichandran, Kodi S.
N1 - Funding Information:
The authors thank members of the Ravichandran laboratory for discussions and critical reading of the manuscript. This work is supported by grants to K.S.R. from NIGMS R35GM122542, the Center for Cell Clearance/University of Virginia School of Medicine, and the Odysseus I Award from the FWO, Belgium. J.S.A.P. was supported by the Cancer Research Institute—Mark Foundation Fellowship (NCI 1K99CA237728-01), the Burroughs Wellcome PDEP award, and the NCI Cancer Research Training Award (5T32CA009109-39), L.S.S. was supported by the American Cancer Society Roaring Fork Valley Postdoctoral Fellowship (130254-PF-17-098-01-CSM) and D.E. is supported by a concerted action grant of Ghent University, Fund for Scientific Research-Flanders and an Excellence of Science (EOS) Grant.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Osteoporosis affects millions worldwide and is often caused by osteoclast induced bone loss. Here, we identify the cytoplasmic protein ELMO1 as an important ‘signaling node’ in osteoclasts. We note that ELMO1 SNPs associate with bone abnormalities in humans, and that ELMO1 deletion in mice reduces bone loss in four in vivo models: osteoprotegerin deficiency, ovariectomy, and two types of inflammatory arthritis. Our transcriptomic analyses coupled with CRISPR/Cas9 genetic deletion identify Elmo1 associated regulators of osteoclast function, including cathepsin G and myeloperoxidase. Further, we define the ‘ELMO1 interactome’ in osteoclasts via proteomics and reveal proteins required for bone degradation. ELMO1 also contributes to osteoclast sealing zone on bone-like surfaces and distribution of osteoclast-specific proteases. Finally, a 3D structure-based ELMO1 inhibitory peptide reduces bone resorption in wild type osteoclasts. Collectively, we identify ELMO1 as a signaling hub that regulates osteoclast function and bone loss, with relevance to osteoporosis and arthritis.
AB - Osteoporosis affects millions worldwide and is often caused by osteoclast induced bone loss. Here, we identify the cytoplasmic protein ELMO1 as an important ‘signaling node’ in osteoclasts. We note that ELMO1 SNPs associate with bone abnormalities in humans, and that ELMO1 deletion in mice reduces bone loss in four in vivo models: osteoprotegerin deficiency, ovariectomy, and two types of inflammatory arthritis. Our transcriptomic analyses coupled with CRISPR/Cas9 genetic deletion identify Elmo1 associated regulators of osteoclast function, including cathepsin G and myeloperoxidase. Further, we define the ‘ELMO1 interactome’ in osteoclasts via proteomics and reveal proteins required for bone degradation. ELMO1 also contributes to osteoclast sealing zone on bone-like surfaces and distribution of osteoclast-specific proteases. Finally, a 3D structure-based ELMO1 inhibitory peptide reduces bone resorption in wild type osteoclasts. Collectively, we identify ELMO1 as a signaling hub that regulates osteoclast function and bone loss, with relevance to osteoporosis and arthritis.
UR - http://www.scopus.com/inward/record.url?scp=85113152804&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-25239-6
DO - 10.1038/s41467-021-25239-6
M3 - Article
C2 - 34404802
AN - SCOPUS:85113152804
SN - 2041-1723
VL - 12
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 4974
ER -